Cas:129768-95-2 (4-methylpyridin-2-yl)methanamine manufacturer & supplier

We serve Chemical Name:(4-methylpyridin-2-yl)methanamine CAS:129768-95-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(4-methylpyridin-2-yl)methanamine

Chemical Name:(4-methylpyridin-2-yl)methanamine
CAS.NO:129768-95-2
Synonyms:(4-methyl-2-pyridyl)methanamine;(4-methyl-2-pyridyl)methylamine;(4-Methylpyridin-2-yl)methylamine;4-methyl-2-aminomethylpyridine;2-(Aminomethyl)-4-picoline;(4-methyl-pyridin-2-yl)methanamine;2-(Aminomethyl)-4-methylpyridine;2-(3-CARBOXYPHENYL)-QUINOLINE-4-CARBOXYLIC ACID;C-(4-methyl-pyridin-2-yl)-methylamine
Molecular Formula:C7H10N2
Molecular Weight:122.16800
HS Code:2933399090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.91000
Exact Mass:122.08400
LogP:1.54900

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (4-methyl-2-pyridyl)methanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,C-(4-methyl-pyridin-2-yl)-methylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-methyl-2-pyridyl)methylamine Use and application,2-(Aminomethyl)-4-methylpyridine technical grade,usp/ep/jp grade.


Related News: These companies need cost-effective, seamless ways to move small molecule compounds from early-phase to commercial according to global quality and regulatory standards, and these expanded facilities at our Nansha site are designed to help them to do so.” 1-(2-bromoethyl)-4-(4-methylthiophenyl)-3-benzylpyrazol-5-ol manufacturers He further explained that getting a new drug to commercial manufacturing is also complex and costly due to the very stringent drug manufacturing regulatory mechanism. 1,3-bis-(α-hydroxy-isopropyl)-5-isopropyl-benzene suppliers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. Methanone, [4-(methylthio)phenyl]-2-naphthalenyl- vendor & factory the strategy lays out the challenges that researchers and institutions are facing, including skills shortages in particular disciplines, limited opportunities for career progression and issues of bullying and harassment.,A major advantage of identifying suitable biocatalysts early on is that it provides ample opportunity for optimization.